PTC Therapeutics PTCT Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's amortization expense related to capitalized debt issuance costs?
- PTC Therapeutics (PTCT) reported amortization expense related to capitalized debt issuance costs of $305K in Q1 2026.
- How has PTC Therapeutics's amortization expense related to capitalized debt issuance costs changed year-over-year?
- PTC Therapeutics's amortization expense related to capitalized debt issuance costs increased by 2.0% year-over-year, from $299K to $305K.
- What is the long-term trend for PTC Therapeutics's amortization expense related to capitalized debt issuance costs?
- Over 4 years (2021 to 2025), PTC Therapeutics's amortization expense related to capitalized debt issuance costs has grown at a -9.9% compound annual growth rate (CAGR), from $1.85M to $1.22M.